The primary efficacy objective for this study is to evaluate the efficacy of a single,
oral dose of BXM compared with placebo to prevent secondary within-household
transmission of influenza A/B.
Criteria:IP's must be between 5 and 64 years old
Test positive for influenza and have influenza symptom onset within 48 hours.
Not at high risk for complications of influenza.
Ip's must live with 1 or more HHC's that have been unvaccinated for influenza within the last 6 months.